Navigation Links
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Date:8/3/2009

ncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
2. AEterna Zentaris Receives US$10 Million from Institutional Investors
3. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
4. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
6. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
7. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
8. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
9. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
10. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
11. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... According to a new market report published by ... (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products and ... and Forecast, 2013 – 2019,”the global agricultural biotechnology market ... is expected to reach USD 28,694.1 million by 2019, ... 2019. , Demand for food production has increased ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... , , , ... AMGN ) today announced detailed results from a Phase ... the treatment of bone metastases in 2,046 patients with advanced ... demonstrated superior efficacy compared to Zometa. These results were presented ...
... ... answer the question, "Is the Jatropha sector becoming a DotCom Bubble?". 2nd JatrophaWorld ... Viridesco Ltd. will discuss the challenges, controversies & paradoxes of the nascent Jatropha non-food ... ...
... has become just another fixture, it,s time to take a ... used to develop paper-based biosensors that can detect certain harmful ... bioterrorism agents. In a paper published in the July ... research team at McMaster University, working with the Sentinel Bioactive ...
Cached Biology Technology:Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 2Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 4Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 5Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 6Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 7Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 8Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 9Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel 2Toxin detection as close as an inkjet printer 2
(Date:2/19/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ... "Military Electro-Optical / Infrared Systems Market by Type, ... Forecast to 2020" report to their offering. ... is expected to reach $16.35 billion by 2020, ... This report segments the military electro-optical/infrared systems market ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... April 2012 -- New techniques for identifying lung cancer ... nanotech ,nose, and a method to examine the cells ... presentations at the 3rd European Lung Cancer Conference (ELCC) ... is vital to improve lung cancer survival rates," commented ...
... new studies that may help doctors tailor lung cancer ... their tumors are being presented at the 3rd European ... of lung cancer treatment is to tailor the treatment ... Christie NHS Foundation Trust in Manchester, UK. "The studies ...
... Patients with advanced non-small cell lung cancer should only ... chemotherapy if their tumor is known to harbor EGFR ... Conference in Geneva, Switzerland. The results of ... that patients with unknown or negative mutation status should ...
Cached Biology News:Early detection techniques offer hope for improved outcomes in lung cancer patients 2Early detection techniques offer hope for improved outcomes in lung cancer patients 3Early detection techniques offer hope for improved outcomes in lung cancer patients 4Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 2New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 3
...
... Edited by R. Edwards ... on all types of immunoassays, ... surface immunoassays and on the ... immunoassays. Essential information is also ...
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: